STOCK TITAN

[Form 4] Oil-Dri Corporation of America Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

On 24 Jul 2025 Kestra Medical Technologies (KMTS) director Raymond W. Cohen filed Form 4 disclosing the automatic conversion and acquisition of 12,994 restricted common shares. The shares arose from previously granted Class A units of West Affum Holdings that converted in conjunction with the company’s IPO; therefore, no cash consideration was paid (transaction code “A”). After the event, Cohen’s beneficial ownership stands at 12,994 KMTS shares held directly.

The award vests in three tranches: 4,331 shares vested immediately on 24 Jul 2025; an additional 4,331 will vest on 24 Jul 2026; and the remaining 4,332 will vest on 24 Jul 2027. The filing shows no open-market purchases, sales, option activity, or derivative positions, and it contains no financial performance metrics.

While the transaction modestly increases insider alignment, the share amount is relatively small and is unlikely to be market-moving by itself.

Il 24 luglio 2025 il direttore di Kestra Medical Technologies (KMTS), Raymond W. Cohen, ha presentato il Modulo 4 per comunicare la conversione automatica e l'acquisizione di 12.994 azioni comuni vincolate. Le azioni derivano da unità di Classe A di West Affum Holdings precedentemente concesse, convertite in concomitanza con l'IPO della società; pertanto, non è stato corrisposto alcun compenso in denaro (codice transazione “A”). Dopo l'operazione, la proprietà effettiva di Cohen ammonta a 12.994 azioni KMTS detenute direttamente.

Il premio si consolida in tre tranche: 4.331 azioni sono state acquisite immediatamente il 24 luglio 2025; ulteriori 4.331 azioni saranno acquisite il 24 luglio 2026; e le restanti 4.332 azioni saranno acquisite il 24 luglio 2027. La comunicazione non evidenzia acquisti o vendite sul mercato aperto, attività di opzioni o posizioni su derivati, e non contiene indicatori di performance finanziaria.

Pur aumentando modestamente l'allineamento degli insider, la quantità di azioni è relativamente contenuta e probabilmente non influenzerà significativamente il mercato da sola.

El 24 de julio de 2025, el director de Kestra Medical Technologies (KMTS), Raymond W. Cohen, presentó el Formulario 4 para revelar la conversión automática y adquisición de 12,994 acciones comunes restringidas. Las acciones provienen de unidades Clase A previamente otorgadas de West Affum Holdings que se convirtieron junto con la oferta pública inicial de la empresa; por lo tanto, no se pagó consideración en efectivo (código de transacción “A”). Tras el evento, la propiedad beneficiaria de Cohen es de 12,994 acciones KMTS en propiedad directa.

El premio se consolida en tres tramos: 4,331 acciones se consolidaron inmediatamente el 24 de julio de 2025; otras 4,331 se consolidarán el 24 de julio de 2026; y las restantes 4,332 se consolidarán el 24 de julio de 2027. El informe no muestra compras o ventas en el mercado abierto, actividad de opciones ni posiciones en derivados, y no contiene métricas de desempeño financiero.

Aunque la transacción incrementa modestamente la alineación de los insiders, la cantidad de acciones es relativamente pequeña y probablemente no moverá el mercado por sí sola.

2025년 7월 24일 Kestra Medical Technologies(KMTS)의 이사 Raymond W. Cohen이 양식 4를 제출하여 12,994주의 제한된 보통주 자동 전환 및 취득을 공시했습니다. 이 주식들은 회사의 IPO와 함께 전환된 West Affum Holdings의 이전에 부여된 Class A 단위에서 발생했으며, 따라서 현금 대가는 지급되지 않았습니다(거래 코드 “A”). 이 사건 이후 Cohen의 실질 소유 주식은 직접 보유한 12,994주 KMTS 주식입니다.

수여 주식은 세 차례에 걸쳐 확정됩니다: 4,331주는 2025년 7월 24일 즉시 확정되었고, 추가 4,331주는 2026년 7월 24일에, 나머지 4,332주는 2027년 7월 24일에 확정됩니다. 제출된 서류에는 공개 시장에서의 매수, 매도, 옵션 활동 또는 파생상품 포지션이 없으며, 재무 성과 지표도 포함되어 있지 않습니다.

이번 거래는 내부자 정렬을 다소 높이지만, 주식 수가 비교적 적어 단독으로 시장에 큰 영향을 미칠 가능성은 낮습니다.

Le 24 juillet 2025, le directeur de Kestra Medical Technologies (KMTS), Raymond W. Cohen, a déposé le formulaire 4 divulguant la conversion automatique et l’acquisition de 12 994 actions ordinaires restreintes. Ces actions proviennent d’unités de classe A de West Affum Holdings précédemment attribuées et converties lors de l’introduction en bourse de la société ; aucune contrepartie en espèces n’a donc été versée (code transaction « A »). Après cet événement, la propriété bénéficiaire de Cohen s’élève à 12 994 actions KMTS détenues directement.

La récompense est acquise en trois tranches : 4 331 actions ont été acquises immédiatement le 24 juillet 2025 ; 4 331 autres seront acquises le 24 juillet 2026 ; et les 4 332 restantes le 24 juillet 2027. Le dépôt ne montre aucune opération sur le marché ouvert, ni activité d’options ou positions sur dérivés, et ne contient aucune mesure de performance financière.

Bien que cette transaction augmente modestement l’alignement des initiés, le nombre d’actions reste relativement faible et est peu susceptible d’avoir un impact significatif sur le marché à lui seul.

Am 24. Juli 2025 reichte der Direktor von Kestra Medical Technologies (KMTS), Raymond W. Cohen, das Formular 4 ein, um die automatische Umwandlung und den Erwerb von 12.994 eingeschränkten Stammaktien offenzulegen. Die Aktien entstanden aus zuvor gewährten Klasse-A-Einheiten von West Affum Holdings, die im Zusammenhang mit dem Börsengang des Unternehmens umgewandelt wurden; daher wurde keine Barzahlung geleistet (Transaktionscode „A“). Nach dem Ereignis hält Cohen 12.994 KMTS-Aktien direkt.

Die Zuteilung erfolgt in drei Tranchen: 4.331 Aktien wurden am 24. Juli 2025 sofort zugeteilt; weitere 4.331 Aktien werden am 24. Juli 2026 zugeteilt; und die verbleibenden 4.332 Aktien am 24. Juli 2027. Die Meldung zeigt keine Käufe oder Verkäufe am offenen Markt, keine Optionsaktivitäten oder Derivatpositionen und enthält keine finanziellen Leistungskennzahlen.

Obwohl die Transaktion die Insider-Ausrichtung leicht erhöht, ist die Anzahl der Aktien relativ gering und wird allein wahrscheinlich keine marktrelevanten Auswirkungen haben.

Positive
  • Director ownership increase: Cohen now holds 12,994 KMTS shares, enhancing alignment with public shareholders.
Negative
  • Limited immediacy: Only 4,331 shares are currently vested; 66% remain restricted until 2026-2027.

Insights

TL;DR: Routine IPO-related share conversion; aligns director but immaterial to valuation.

The Form 4 records a non-cash grant that brings Cohen’s direct stake to 12,994 shares. Given KMTS’s likely post-IPO float, this holding is negligible from a supply-demand standpoint. The staged vesting maintains long-term alignment but also limits immediate tradable float. No buy/sell signals or valuation insight can be drawn; therefore impact on stock price should be neutral.

TL;DR: Standard equity incentive; positive alignment, but governance impact modest.

The conversion follows typical IPO clean-up mechanics, shifting partnership units into listed equity. Multi-year vesting supports retention and aligns director incentives with shareholder value creation through 2027. No red flags—authority covered by existing PoA. However, the quantum is small, so governance leverage remains limited.

Il 24 luglio 2025 il direttore di Kestra Medical Technologies (KMTS), Raymond W. Cohen, ha presentato il Modulo 4 per comunicare la conversione automatica e l'acquisizione di 12.994 azioni comuni vincolate. Le azioni derivano da unità di Classe A di West Affum Holdings precedentemente concesse, convertite in concomitanza con l'IPO della società; pertanto, non è stato corrisposto alcun compenso in denaro (codice transazione “A”). Dopo l'operazione, la proprietà effettiva di Cohen ammonta a 12.994 azioni KMTS detenute direttamente.

Il premio si consolida in tre tranche: 4.331 azioni sono state acquisite immediatamente il 24 luglio 2025; ulteriori 4.331 azioni saranno acquisite il 24 luglio 2026; e le restanti 4.332 azioni saranno acquisite il 24 luglio 2027. La comunicazione non evidenzia acquisti o vendite sul mercato aperto, attività di opzioni o posizioni su derivati, e non contiene indicatori di performance finanziaria.

Pur aumentando modestamente l'allineamento degli insider, la quantità di azioni è relativamente contenuta e probabilmente non influenzerà significativamente il mercato da sola.

El 24 de julio de 2025, el director de Kestra Medical Technologies (KMTS), Raymond W. Cohen, presentó el Formulario 4 para revelar la conversión automática y adquisición de 12,994 acciones comunes restringidas. Las acciones provienen de unidades Clase A previamente otorgadas de West Affum Holdings que se convirtieron junto con la oferta pública inicial de la empresa; por lo tanto, no se pagó consideración en efectivo (código de transacción “A”). Tras el evento, la propiedad beneficiaria de Cohen es de 12,994 acciones KMTS en propiedad directa.

El premio se consolida en tres tramos: 4,331 acciones se consolidaron inmediatamente el 24 de julio de 2025; otras 4,331 se consolidarán el 24 de julio de 2026; y las restantes 4,332 se consolidarán el 24 de julio de 2027. El informe no muestra compras o ventas en el mercado abierto, actividad de opciones ni posiciones en derivados, y no contiene métricas de desempeño financiero.

Aunque la transacción incrementa modestamente la alineación de los insiders, la cantidad de acciones es relativamente pequeña y probablemente no moverá el mercado por sí sola.

2025년 7월 24일 Kestra Medical Technologies(KMTS)의 이사 Raymond W. Cohen이 양식 4를 제출하여 12,994주의 제한된 보통주 자동 전환 및 취득을 공시했습니다. 이 주식들은 회사의 IPO와 함께 전환된 West Affum Holdings의 이전에 부여된 Class A 단위에서 발생했으며, 따라서 현금 대가는 지급되지 않았습니다(거래 코드 “A”). 이 사건 이후 Cohen의 실질 소유 주식은 직접 보유한 12,994주 KMTS 주식입니다.

수여 주식은 세 차례에 걸쳐 확정됩니다: 4,331주는 2025년 7월 24일 즉시 확정되었고, 추가 4,331주는 2026년 7월 24일에, 나머지 4,332주는 2027년 7월 24일에 확정됩니다. 제출된 서류에는 공개 시장에서의 매수, 매도, 옵션 활동 또는 파생상품 포지션이 없으며, 재무 성과 지표도 포함되어 있지 않습니다.

이번 거래는 내부자 정렬을 다소 높이지만, 주식 수가 비교적 적어 단독으로 시장에 큰 영향을 미칠 가능성은 낮습니다.

Le 24 juillet 2025, le directeur de Kestra Medical Technologies (KMTS), Raymond W. Cohen, a déposé le formulaire 4 divulguant la conversion automatique et l’acquisition de 12 994 actions ordinaires restreintes. Ces actions proviennent d’unités de classe A de West Affum Holdings précédemment attribuées et converties lors de l’introduction en bourse de la société ; aucune contrepartie en espèces n’a donc été versée (code transaction « A »). Après cet événement, la propriété bénéficiaire de Cohen s’élève à 12 994 actions KMTS détenues directement.

La récompense est acquise en trois tranches : 4 331 actions ont été acquises immédiatement le 24 juillet 2025 ; 4 331 autres seront acquises le 24 juillet 2026 ; et les 4 332 restantes le 24 juillet 2027. Le dépôt ne montre aucune opération sur le marché ouvert, ni activité d’options ou positions sur dérivés, et ne contient aucune mesure de performance financière.

Bien que cette transaction augmente modestement l’alignement des initiés, le nombre d’actions reste relativement faible et est peu susceptible d’avoir un impact significatif sur le marché à lui seul.

Am 24. Juli 2025 reichte der Direktor von Kestra Medical Technologies (KMTS), Raymond W. Cohen, das Formular 4 ein, um die automatische Umwandlung und den Erwerb von 12.994 eingeschränkten Stammaktien offenzulegen. Die Aktien entstanden aus zuvor gewährten Klasse-A-Einheiten von West Affum Holdings, die im Zusammenhang mit dem Börsengang des Unternehmens umgewandelt wurden; daher wurde keine Barzahlung geleistet (Transaktionscode „A“). Nach dem Ereignis hält Cohen 12.994 KMTS-Aktien direkt.

Die Zuteilung erfolgt in drei Tranchen: 4.331 Aktien wurden am 24. Juli 2025 sofort zugeteilt; weitere 4.331 Aktien werden am 24. Juli 2026 zugeteilt; und die verbleibenden 4.332 Aktien am 24. Juli 2027. Die Meldung zeigt keine Käufe oder Verkäufe am offenen Markt, keine Optionsaktivitäten oder Derivatpositionen und enthält keine finanziellen Leistungskennzahlen.

Obwohl die Transaktion die Insider-Ausrichtung leicht erhöht, ist die Anzahl der Aktien relativ gering und wird allein wahrscheinlich keine marktrelevanten Auswirkungen haben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Ryan Amy

(Last) (First) (Middle)
410 N. MICHIGAN AVE, SUITE 400

(Street)
CHICAGO IL 60611

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oil-Dri Corp of America [ ODC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/23/2025 S 1,000 D $60.62 2,900 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Anthony W. Parker by Power of Attorney 07/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KMTS director Raymond W. Cohen report in the Form 4 filed on July 24, 2025?

He reported the automatic acquisition of 12,994 restricted common shares due to IPO-related unit conversion.

How many KMTS shares does Cohen own after the reported transaction?

Cohen beneficially owns 12,994 common shares, all held directly.

Was any cash paid for the 12,994 KMTS shares?

No. The shares were received through an automatic conversion; no purchase price was involved.

What is the vesting schedule for the restricted KMTS shares?

4,331 shares vested on 7/24/25; another 4,331 vest on 7/24/26; the final 4,332 vest on 7/24/27.

Does the filing indicate insider buying or selling activity?

It indicates an award conversion, not an open-market buy or sale; no shares were sold.
Oil-Dri Corporation of America

NYSE:ODC

ODC Rankings

ODC Latest News

ODC Latest SEC Filings

ODC Stock Data

892.05M
9.84M
3.98%
69.07%
0.85%
Specialty Chemicals
Miscellaneous Manufacturing Industries
Link
United States
CHICAGO